Skip to NavigationSkip to content

Amarin appoints Jan van Heek

Published on: 15/02/10

Jan van Heek has joined Amarin’s board of directors of as a non-executive director and will also take on the role of chairman of the Dublin-based company’s audit committee.

His healthcare career spans more than 30 years in the healthcare industry and he is currently a principal and partner at advisory company BioPoint.

Prior to establishing BioPoint, Jan spent more than 18 years at Genzyme, most recently as senior advisor to the chief executive and senior management team.

He joined Genzyme in 1991 where, as executive vice president, he was largely responsible for establishing and building its worldwide therapeutics, surgical and genetic testing businesses.

"Jan van Heek has a wealth of industry experience derived from helping to build one of the world's largest and most successful biotech companies," commented Joseph Zakrzewski, executive chairman of Amarin. "We are very pleased he will bring this knowledge to support Amarin as we strive to create a valuable company focused on new products to improve the treatment of cardiovascular diseases."

Prior to Genzyme, Jan held various management positions at Baxter Healthcare in Europe and the US.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches